GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement
- None.
- None.
A reverse stock split is a strategic move often undertaken by companies to boost their share price and maintain compliance with exchange listing requirements. In this case, GeoVax Labs is implementing a 1-for-15 reverse stock split to meet Nasdaq's minimum bid price rule. From a financial perspective, this move is expected to reduce the number of shares outstanding from approximately 29.8 million to just under 2 million. While this does not inherently change the company's market capitalization, it does increase the price per share, which could make the stock more appealing to institutional investors who may avoid stocks priced under certain thresholds.
However, investors should be aware that reverse splits can be perceived negatively as it may signal underlying issues with the company's performance or growth prospects. It's also crucial to monitor the stock's performance post-split to ensure that the intended benefits, such as improved liquidity and marketability, materialize. The adjustment of the publicly traded warrants to 15 warrants for one share at a price of $75 may affect the attractiveness of these warrants to investors, as it alters the previous terms under which they were purchased.
GeoVax Labs' reverse stock split reflects a tactical response to market conditions and regulatory requirements. Historically, reverse splits have had mixed outcomes on company stock performance. While they can lead to a temporary increase in share price, the long-term effects vary and may not always result in sustained investor interest or stock appreciation. The company's ability to maintain a higher stock price over time will largely depend on its operational success and progress in developing its immunotherapies and vaccines.
It's also important to consider the market's perception of reverse stock splits in the biotechnology sector, where investment is often driven by product pipelines, clinical trial results and regulatory milestones. Investors should evaluate GeoVax Labs' fundamentals, including its R&D pipeline, recent clinical trial data and overall financial health, to better understand the potential impact of the reverse split on the company's future performance.
From a legal standpoint, GeoVax Labs has followed due process by obtaining stockholder approval for the reverse stock split, as per corporate governance norms. The company's adherence to Nasdaq Listing Rule 5550(a)(2) by effecting the reverse split to regain compliance is a necessary legal step to avoid delisting. Investors should note that while the rights and privileges of the shareholders remain substantially unaffected, the conversion of shares and adjustment of warrants may require careful scrutiny to understand the legal implications, especially regarding the rounding up of fractional shares and the recalibration of the warrants' exercise price and ratio.
Shareholders should also be informed about the potential for dilution if the company issues additional shares in the future, which is a common occurrence post-reverse split. The company's communication and transparency with its shareholders regarding the reverse split process and its potential effects are critical to maintaining shareholder trust and ensuring legal compliance.
ATLANTA, GA, Jan. 29, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that the Company's Board of Directors has approved a reverse stock split of its issued and outstanding shares of common stock, par value
The reverse stock split will become effective on January 30, 2024 (the "Effective Date"), and the Common Stock is expected to begin trading on the split-adjusted basis on the Nasdaq Stock Exchange ("Nasdaq") at the market open on January 31, 2024. Following the reverse split, the Common Stock will continue to trade under the symbol “GOVX”, and the Company’s publicly traded warrants will continue to trade under the symbol “GOVXW”.
On the Effective Date, every 15 issued and outstanding shares of the Company's Common Stock will be converted automatically into one share of the Company's Common Stock without any change in the par value per share. The total number of issued and outstanding shares of Common Stock will therefore be reduced proportionately from 29,757,823 shares to approximately 1,983,855 shares. On the Effective Date, the publicly traded warrants will be adjusted to require fifteen (15) warrants to be exercised to receive one (1) share of common stock at a price of
Immediately after the reverse stock split, each stockholder's percentage ownership interest in the Company and proportional voting power will remain unchanged, except for minor changes and adjustments that will result from the rounding up of any fractional shares to the next whole number of shares. The rights and privileges of the holders of shares of Common Stock will be substantially unaffected by the reverse stock split.
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel therapies and vaccines for solid tumor cancers and many of the world’s most threatening infectious diseases. The company’s lead program in oncology is a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, presently in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax’s lead infectious disease candidate is GEO-CM04S1, a next-generation COVID-19 vaccine targeting high-risk immunocompromised patient populations. Currently in three Phase 2 clinical trials, GEO-CM04S1 is being evaluated as a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, and as a booster vaccine in patients with chronic lymphocytic leukemia (CLL). In addition, GEO-CM04S1 is in a Phase 2 clinical trial evaluating the vaccine as a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. GeoVax has a leadership team who have driven significant value creation across multiple life science companies over the past several decades. For more information, visit our website: www.geovax.com.
Forward-Looking Statements
This release contains forward-looking statements regarding GeoVax’s business plans. The words “believe,” “look forward to,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax’s immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax’s viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax’s immuno-oncology products and preventative vaccines will be safe for human use, GeoVax’s vaccines will effectively prevent targeted infections in humans, GeoVax’s immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax’s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.
Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.
| Company Contact: | Investor Relations Contact: | Media Contact: | ||
| info@geovax.com | paige.kelly@sternir.com | sr@roberts-communications.com | ||
| 678-384-7220 | 212-698-8699 | 202-779-0929 | ||
FAQ
What is the reverse stock split ratio announced by GeoVax Labs, Inc. (GOVX)?
When will the reverse stock split be effective for GeoVax Labs, Inc. (GOVX)?
What will be the impact of the reverse stock split on the total number of issued and outstanding shares of Common Stock for GeoVax Labs, Inc. (GOVX)?
Will the reverse stock split affect the rights and privileges of the holders of shares of Common Stock for GeoVax Labs, Inc. (GOVX)?
